Atlas Trials

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04613557 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04613557
Sponsor
Celyad Oncology SA
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapse/Refractory Multiple Myeloma
Start date
2020-11-16
Primary completion
2022-12-21
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.